Navigation Links
JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers
Date:11/14/2007

- $3 Million Grant Over Three Years from Lilly Foundation Could 'Fill a

Major Gap' in Diabetes Science -

NEW YORK, Nov. 14 /PRNewswire-FirstCall/ -- The Juvenile Diabetes Research Foundation and Eli Lilly and Company announced today that they are joining together to create a $3 million research effort to accelerate the pace of research into drugs and therapies to cure diabetes and its complications by developing biomarkers -- indicators that can measure the progress of disease and the effectiveness of therapeutics.

The project -- called the JDRF-Lilly Innovative and Academic Research and Development Grants in Diabetes Biomarkers -- will be funded by a $3 million grant from the Lilly Foundation to JDRF over three years.

JDRF is one of the world's largest charitable funder of type 1 diabetes research; over the last year, JDRF has funded more than $137 million in research to cure and develop therapeutics for type 1 diabetes and its complications. Lilly is a global leader in diabetes science and treatment, dating back to the development of the world's first commercially-available insulin in the 1920s, and continues to pioneer research to develop innovative medicines to address the unmet needs of people with diabetes.

The new JDRF-Lilly project will support cutting-edge research on biomarkers for pancreatic beta cell mass and function.

Biomarkers are natural features (lab values, images, or clinical features) whose detection indicates the presence of a particular disease state, or correlates with the risk or progression of a disease; for example, elevated prostate specific antigen is a molecular biomarker for prostate cancer. Two of the best-known biomarkers are cholesterol and blood pressure levels, which denote key information about cardiovascular health. In evaluating potential therapeutics, biomarkers can also serve as "surrogate endpoints" for evaluating the clinical benefit of a treatment.

"In genera
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
2. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer
3. Lilly and Glenmark Pharmaceuticals Announce License Agreement
4. Lilly Receives NCQA Design Certification for Depression Care Management Program
5. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
6. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
7. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
9. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
10. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
11. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... VIEJO, Calif. , Dec. 22, 2014 ... into expanded corporate offices in Aliso Viejo ... announced that due to the tremendous growth and worldwide ... needed. Sales of patented SnoreRx, the anti snore cure ... offices. He said, "We are now in 23 ...
(Date:12/22/2014)... 22, 2014 Research and Markets ... the "Investment Analysis of the US Medical ... http://photos.prnewswire.com/prnh/20130307/600769 ... medical device sector identifies the key trends and ... investments, and mergers and acquisitions. The ...
(Date:12/22/2014)... , Dec. 22, 2014 Swedish Orphan ... today announced that the Committee for Medicinal Products for ... has adopted a positive opinion for the use of ... men with Peyronie,s disease with a palpable plaque and ... start of therapy. The use of Xiapex ...
Breaking Medicine Technology:Investment Analysis of the US Medical Device Sector 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 2Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 3Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 4Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 5Sobi's Xiapex receives positive opinion by CHMP for the treatment of Peyronie's disease 6
... July 27 Timothy Mastro,MD, FACP, DTM&H, who ... Senior Director of Research, will share information on ... at the,International AIDS Conference in Mexico City., ... Trials," will examine ongoing and upcoming clinical trials ...
... advance the company,s clinical development programs and ... CombiPlex(TM) technology ... privately held pharmaceutical company developing novel,products based on proven ... excess of $22.5 million in a Series C private,equity ...
Cached Medicine Technology:HIV Prevention Expert Dr. Timothy Mastro Speaks on Future of Pre-Exposure Prophylaxis at International AIDS Conference 2Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million 2Celator Pharmaceuticals Raises Series C Financing in Excess of $22.5 Million 3
(Date:12/25/2014)... (PRWEB) December 26, 2014 The ... CAGR of 7.2% to reach $5,756.0 million by ... the microscopy market. The electron microscopes product segment ... the forecast period. , Rising focus on nanotechnology, ... growth of the microscopy market. , Get Full ...
(Date:12/25/2014)... TX (PRWEB) December 26, 2014 ... Market Analysis to 2023” focuses on the current ... opportunities in the colorectal cancer market. Stivarga is ... of colon or rectal cancer. Boehringer Ingelheim is ... for the treatment of refractory CRC in the ...
(Date:12/25/2014)... 2014 “Every three months the trends for ... sweetheart evening dress will be one of the hottest styles ... Yunx.co.uk says. Today, the company releases 26 A-line sweetheart evening ... 80% off. , “We are trying our best to ... our latest designs. Along with affordable prices, we provide discounted ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... Woodland Hills, California (PRWEB) December 25, 2014 ... in her home in Woodland Hills, California after an ... Harris passed away on Christmas Eve evening in her ... battle with aggressive metastatic breast cancer. ... International for over forty years, she pioneered and championed ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... in Ongoing Research to Replicate Insulin-Producing Function of Healthy ... SANTA BARBARA, Calif., March 31 A key step ... patients with diabetes has been achieved, according to new ... Technology & Therapeutics .Researchers at the University of ...
... refractory patients recruited in trial;, ... complete efficacy data to be available in ... Life Sciences Inc. (TSX: BNC), a research-based, technology-driven ... completed recruitment in its initial Phase III registration ...
... in The Journal of Nursing Administration shows ... continuous vigilance monitoring is used on medical-surgical unit beds. ... President and CEO of Hoana Medical, Inc. "Using ... potential patient deterioration so they can respond appropriately. ...
... magazine for medical device makers appoints Full Spectrum Software’s Andrew Dallas ... premier magazine for the medical device industry has appointed Andrew Dallas ... president and CTO of Full Spectrum Software company background ... ...
... Urgent Care Center. Hoboken residents now have much needed option for treatment ... ... -- Hoboken families now have a convenient place to go for most ... Hoboken,s first Urgent Care center and a medical facility like no other ...
... ... Alpharetta, Ga. (PRWEB) March 31, 2009 -- Among 1,239 ... had not worked at a government healthcare facility at least once. ... in trying government locum tenens jobs. This is good news ...
Cached Medicine News:Health News:Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas 2Health News:Researchers Successfully Create Computer-Simulated Model for Evaluating Artificial Pancreas 3Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 2Health News:Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM) 3Health News:Continuous Vigilance Monitoring Technology Benefits Nurses & Patients 2Health News:Andrew Dallas, President of Full Spectrum Software Appointed to Medical Device and Diagnostic Industry Magazine Editorial Advisory Board 2Health News:PromptMD Announces the Opening of their First Urgent Care Center at 309 First Street in Hoboken 2Health News:Physician Survey Highlights Advantages of Government Locum Tenens Jobs 2Health News:Physician Survey Highlights Advantages of Government Locum Tenens Jobs 3
... is a leading provider of immunofluorescence assays, ... menu that includes kits for autoimmune diseases, ... miscellaneous conjugates and components. Our Impact IFA ... of substrates and kit sizes to choose ...
... Medical Professional Diagnostics is a leading provider ... and DFA test menu that includes kits ... as well as miscellaneous conjugates and components. ... a wide assortment of substrates and kit ...
... ELISA products make us a leader in ... faster integration into the busy laboratory, our ... and run-to-run consistency. Our Infectious Disease ELISA ... wide range of serological assays including ToRCH, ...
... Diagnostics is a leading provider of immunofluorescence ... test menu that includes kits for autoimmune ... as miscellaneous conjugates and components. Our Impact ... assortment of substrates and kit sizes to ...
Medicine Products: